An ex Vivo Model Enables Systematic Investigation of the Intestinal Absorption and Transcytosis of Oral Particulate Nanocarriers
Source abstract
Abstract
Nanoparticulate formulations are being developed toward enhancing the bioavailability of orally administrated biologics. However, the processes mediating particulate carriers' intestinal uptake and transport remains to be fully elucidated. Herein, an optical clearing-based whole tissue mount/imaging strategy was developed to enable high quality microscopic imaging of intestinal specimens. It enabled the distribution of nanoparticles within intestinal villi to be quantitatively analyzed at a cellular level. Two-hundred and fifty nm fluorescent polystyrene nanoparticles were modified with polyethylene glycol (PEG), Concanavalin A (ConA), and pectin to yield mucopenetrating, enterocyte targeting, and mucoadhesive model nanocarriers, respectively. Introducing ConA on the PEGylated nanoparticles significantly increased their uptake in the intestinal epithelium (∼4.16 fold for 200 nm nanoparticle and ∼2.88 fold for 50 nm nanoparticles at 2 h). Moreover, enterocyte targeting mediated the trans-epithelial translocation of 50 nm nanoparticles more efficiently than that of the 200 nm nanoparticles. This new approach provides an efficient methodology to obtain detailed insight into the transcytotic activity of enterocytes as well as the barrier function of the constitutive intestinal mucus. It can be applied to guide the rational design of particulate formulations for more efficient oral biologics delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Inhalation and Respiratory Drug Delivery · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Future Industries Institute and ARC Centre of Excellence Convergent Bio-Nano Science and Technology, University of South Australia, Mawson Lakes Campus, Adelaide, South Australia 5095, Australia
UniSA Clinical and Health Science and ARC Centre of Excellence Convergent Bio-Nano Science and Technology, University of South Australia, City West Campus, Adelaide, South Australia 5000, Australia
Funding
Australian Research Council
References (55)
Show source-provided references
1. 10.1016/j.jconrel.2016.06.01610.1016/j.jconrel.2016.06.016 ↗
2. 10.1615/CritRevTherDrugCarrierSyst.v20.i23.3010.1615/CritRevTherDrugCarrierSyst.v20.i23.30 ↗
3. 10.1038/nrclinonc.2010.8210.1038/nrclinonc.2010.82 ↗
4. 10.1016/j.addr.2012.11.00510.1016/j.addr.2012.11.005 ↗
5. 10.1016/j.addr.2012.10.00710.1016/j.addr.2012.10.007 ↗
6. 10.1016/j.addr.2013.01.00210.1016/j.addr.2013.01.002 ↗
7. 10.2174/13892001079111083610.2174/138920010791110836 ↗
8. 10.1016/j.addr.2017.10.00910.1016/j.addr.2017.10.009 ↗
9. 10.1016/j.jconrel.2012.02.00610.1016/j.jconrel.2012.02.006 ↗
10. 10.1016/j.addr.2011.12.00910.1016/j.addr.2011.12.009 ↗
11. 10.1002/mabi.20170006010.1002/mabi.201700060 ↗
12. 10.1016/S0169-409X(01)00231-910.1016/S0169-409X(01)00231-9 ↗
13. 10.1016/j.jconrel.2014.10.02610.1016/j.jconrel.2014.10.026 ↗
14. 10.1016/j.ejpb.2014.12.02110.1016/j.ejpb.2014.12.021 ↗
15. 10.1016/j.ejpb.2015.11.00310.1016/j.ejpb.2015.11.003 ↗
16. 10.1016/j.jconrel.2011.08.03210.1016/j.jconrel.2011.08.032 ↗
17. 10.1016/j.addr.2015.09.01210.1016/j.addr.2015.09.012 ↗
18. 10.1039/C7NR06821B10.1039/C7NR06821B ↗
19. 10.1016/j.nano.2016.11.01710.1016/j.nano.2016.11.017 ↗
20. 10.1039/C8BM00664D10.1039/C8BM00664D ↗
21. 10.1016/j.jconrel.2007.06.02410.1016/j.jconrel.2007.06.024 ↗
22. 10.1016/j.biomaterials.2014.10.03810.1016/j.biomaterials.2014.10.038 ↗
23. 10.1126/scitranslmed.300704910.1126/scitranslmed.3007049 ↗
24. 10.1073/pnas.130588211010.1073/pnas.1305882110 ↗
25. 10.1016/j.biomaterials.2010.04.02110.1016/j.biomaterials.2010.04.021 ↗
26. 10.1016/j.jconrel.2017.11.01210.1016/j.jconrel.2017.11.012 ↗
27. 10.1111/j.1365-2982.2010.01657.x10.1111/j.1365-2982.2010.01657.x ↗
28. 10.18433/J3NP5N10.18433/J3NP5N ↗
29. 10.1016/j.ejps.2013.08.01810.1016/j.ejps.2013.08.018 ↗
30. 10.3762/bjnano.5.23910.3762/bjnano.5.239 ↗
31. 10.1038/s41551-020-0545-610.1038/s41551-020-0545-6 ↗
32. 10.1039/C9BM00058E10.1039/C9BM00058E ↗
33. 10.1038/nprot.2014.12310.1038/nprot.2014.123 ↗
34. 10.1038/srep3433110.1038/srep34331 ↗
35. 10.1021/acsnano.6b0187910.1021/acsnano.6b01879 ↗
36. 10.3109/1061186100373394610.3109/10611861003733946 ↗
37. 10.1016/j.colsurfa.2013.12.00610.1016/j.colsurfa.2013.12.006 ↗
38. 10.1039/c2jm30210a10.1039/c2jm30210a ↗
39. 10.1002/admt.20180072610.1002/admt.201800726 ↗
40. 10.1016/j.ijpharm.2020.12016710.1016/j.ijpharm.2020.120167 ↗
41. 10.1016/j.jcmgh.2015.12.00410.1016/j.jcmgh.2015.12.004 ↗
42. 10.1098/rsob.17025610.1098/rsob.170256 ↗
43. 10.1021/mp400507g10.1021/mp400507g ↗
44. 10.1016/j.addr.2005.07.00110.1016/j.addr.2005.07.001 ↗
45. Sundar Raj A. · Sci. Rep. · 2012 · 1 · 550
46. 10.1016/j.progpolymsci.2014.07.01010.1016/j.progpolymsci.2014.07.010 ↗
47. 10.1016/j.addr.2008.11.00210.1016/j.addr.2008.11.002 ↗
48. 10.1073/pnas.090599810610.1073/pnas.0905998106 ↗
49. 10.1016/S0032-3861(96)00859-210.1016/S0032-3861(96)00859-2 ↗
50. 10.7150/thno.1428010.7150/thno.14280 ↗
51. 10.1016/S0144-8617(03)00158-910.1016/S0144-8617(03)00158-9 ↗
52. 10.1021/la301390u10.1021/la301390u ↗
53. 10.1002/adma.20080099810.1002/adma.200800998 ↗
54. 10.1016/j.jconrel.2006.08.01310.1016/j.jconrel.2006.08.013 ↗
55. 10.1016/j.addr.2007.05.01710.1016/j.addr.2007.05.017 ↗